Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 19/20 | 0.49 |
| ▸ | SYK | P43405 | 1/20 | 0.48 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.44 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.44 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.44 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15463222 | 0.86 | SYK (0.46) | PIK3CASYKPIK3R1 | |
| SCHEMBL612648 | 0.84 | PIK3CA (0.46) | PIK3CAPIK3CDPIK3CBPIK3CGPIK3R1 | |
| SCHEMBL10141666 | 0.82 | PIK3CA (0.47) | PIK3CAPIK3CDPIK3CBPIK3CGPIK3R1 | |
| SCHEMBL21190907 | 0.78 | LRRK2 (0.42) | PIK3CASYK | |
| SCHEMBL10196382 | 0.74 | SYK (0.67) | PIK3CASYKPIK3R1 | |
| SCHEMBL10196332 | 0.73 | SYK (0.50) | PIK3CASYKPIK3R1 | |
| SCHEMBL10084731 | 0.73 | ACHE (0.44) | PIK3CAPIK3CDPIK3CG | |
| SCHEMBL7362112 | 0.72 | PDE4D (0.50) | — | |
| SCHEMBL7358483 | 0.71 | PDE4D (0.49) | PIK3CAPIK3CDPIK3CBPIK3CGPIK3R1 | |
| SCHEMBL11918290 | 0.71 | PDE4B (0.40) | PIK3CAPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3808739-A1 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | Vertex Pharmaceuticals Incorporated (US) | 2021-04-21 | — | — | EP | disclosed |
| EP-3309152-B1 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMA (US) | 2020-09-09 | — | — | EP | disclosed |
| EP-3309152-A1 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | Vertex Pharmaceuticals Incorporated (US) | 2018-04-18 | — | — | EP | disclosed |
| EP-2516417-B1 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMA (US) | 2017-10-11 | — | — | EP | disclosed |
| US-20170260175-A1 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMACEUTICALS INCORPORATED | 2017-09-14 | — | — | US | disclosed |
| US-8466288-B2 | Isoindolinone inhibitors of phosphatidylinositol 3-kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170260175-A1 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | PIK3CD, PIK3CA, PIK3R5 | PIK3CA 2/4885SYK 1192/4885PIK3CD 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.